Human EGF R, His Tag, low endotoxin (EGR-H522a) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 645 (Accession # P00533-1).
Predicted N-terminus: Leu 25
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.5kDa. The protein migrates as 110-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 0.01 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 6 months under sterile conditions after reconstitution.
Human EGF R, His Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Cetuximab at 2 μg/mL (100 μL/well) can bind Human EGF R, His Tag, low endotoxin (Cat. No. EGR-H522a) with a linear range of 0.8-6 ng/mL (QC tested).
Immobilized Erbitux on CM5 Chip via anti-human Fc IgG, can bind Human EGF R, His Tag, low endotoxin (Cat.No. EGR-H522a) with an affinity constant of 0.492 nM as determined in SPR assay (Biacore T200) ( Routinely tested).
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.